Medicenna to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced Dr. Fahar Merchant, President and CEO, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference, scheduled virtually from February 14 – 18, 2022. The chat will take place on February 16 at 8:00am ET. A webcast link for the event is available, and replay details can be found on Medicenna's Investor Relations website. Medicenna focuses on innovative immunotherapies, notably its IL-2 Superkine, MDNA11, and IL-4 Empowered Superkine, MDNA55.

News Market Reaction – MDNA

-4.81%

-4.81% Session move

In the trading session that priced this news, MDNA declined 4.81%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO and HOUSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a Fireside Chat at the SVB Leerink Global Healthcare Conference, which is scheduled to take place virtually from February 14 – February 18, 2022.

Details are as follows:

11^th Annual SVB Leerink Global Healthcare Conference

Date:	Wednesday, February 16th
Time:	8:00am ET
Format:	Fireside Chat
Location:	Webcast Link

Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

When will Dr. Fahar Merchant present at the SVB Leerink Global Healthcare Conference?

Dr. Fahar Merchant will present on February 16, 2022, at 8:00am ET.

How can I access the webcast of Medicenna's Fireside Chat?

You can access the webcast through the provided webcast link.

What is the main focus of Medicenna Therapeutics?

Medicenna Therapeutics is focused on developing immunotherapies, specifically IL-2, IL-4, and IL-13 Superkines.

What notable therapies is Medicenna developing?

Medicenna is developing MDNA11, an IL-2 Superkine, and MDNA55, an IL-4 Empowered Superkine, which has Fast-Track status from the FDA.

Where can I find more information about Medicenna's events?

Visit the Investor Relations section of Medicenna's website for more information on events and updates.